On February 17, 2022, Chen, Yi published a patent.SDS of cas: 87486-34-8 The title of the patent was Preparation of heterocyclic compounds as BTK inhibitors, and dosage form compositions comprising an inhibitor of BTK and mutants thereof. And the patent contained the following:
Provided herewith are pharmaceutical tablet compositions comprising an organic acid (such as fumaric acid) and a compound of formula I, or an N-oxide thereof, solvate, polymorph, tautomer, stereoisomer, an isotopic form, or a prodrug of said compound of formula I or N-oxide thereof: wherein the compound of formula I is an inhibitor of Bruton’ s tyrosine kinase. Compounds of formula I wherein Q3 is 5-membered heteroaryl; m and n are independently 0, 1, 2, 3 and 4; R1 and R5 are independently H, D, alkyl,spiroalkyl, alkenyl, etc.; and their tablet compositions comprising organic acids, N-oxides, polymorphs, tautomers, stereoisomers, isotopic forms, and prodrugs, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were formulated as tablets and tested for pharmacokinetic properties (data given). The experimental process involved the reaction of 3,5-Dibromo-1-methylpyrazin-2(1H)-one(cas: 87486-34-8).SDS of cas: 87486-34-8
The Article related to heterocyclyl preparation btk inhibitor dosage form, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.SDS of cas: 87486-34-8